RxDoctor Payments DataLook up a doctor →

George Li, MD

Neurology · Port Charlotte, FLNPI 1871668368

Payments from drug & device makers

$2,090,339in general payments, 2019–2025

Across 637 payments — averaging $3281.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$1.3M
  • Argenx US, Inc.$533K
  • Regeneron$80K
  • Takeda Pharmaceuticals U.S.A., Inc.$76K
  • AstraZeneca$56K
  • Sunovion Pharmaceuticals Inc.$40K
  • plus $53K from 54 others
$1,926in research payments, 2019–2025

Across 10 payments — averaging $192.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC41$1,252,504
Argenx US, Inc.40$532,965
Regeneron32$79,723
Takeda Pharmaceuticals U.S.A., Inc.25$76,196
AstraZeneca7$56,329
Sunovion Pharmaceuticals Inc.26$39,680
UCB Biosciences Inc.3$33,352
AbbVie(2 entities)84$5,223
UCB SA1$4,604
Biogen16$1,320
Pfizer11$866
Novartis51$832
Lilly USA, LLC27$591
Amgen31$511
CSL Behring8$494
EMD Serono, Inc.31$490
UCB, Inc.23$435
Johnson & Johnson(2 entities)11$412
Teva Pharmaceuticals USA, Inc.18$325
Amneal Pharmaceuticals LLC11$226
Eisai Inc.9$209
Otsuka America Pharmaceutical, Inc.9$203
Canon Medical Systems USA, Inc.2$198
Alnylam Pharmaceuticals Inc.7$174
Mallinckrodt Hospital Products Inc.6$160
Janssen Scientific Affairs, LLC1$149
Acadia Pharmaceuticals Inc7$145
Neurocrine Biosciences, Inc.6$138
Biohaven Pharmaceuticals, Inc.11$138
Lundbeck LLC7$134
SK Life Science, Inc.5$127
Adamas Pharmaceuticals, Inc.6$125
Avion Pharmaceuticals5$108
Acorda Therapeutics, Inc5$106
Catalyst Pharmaceuticals, Inc.2$79
Azurity Pharmaceuticals, Inc.4$68
Harmony Biosciences LLC4$65
Tanabe Pharma America, Inc.2$58
Biohaven Pharmaceutical Holding Company Ltd.2$56
Abbott2$55
Vanda Pharmaceuticals Inc.2$50
Genentech USA, Inc.2$48
Supernus Pharmaceuticals, Inc.3$47
Scilex Pharmaceuticals Inc.2$44
Livanova USA, Inc.2$41
Saol Therapeutics Inc.2$40
E.r. Squibb & Sons, L.L.C.2$39
Kyowa Kirin, Inc.2$39
Neurelis, Inc.2$38
Bristol Myers Squibb2$37
MDD US Operations, LLC2$36
Alafair Biosciences, Inc.1$32
GE HealthCare2$30
TG Therapeutics, Inc.1$29
Almatica Pharma LLC1$29
Jazz Pharmaceuticals Inc.2$26
Impel Pharmaceuticals Inc.1$25
Upsher-smith Laboratories LLC1$23
Novo Nordisk1$23
Octapharma USA, Inc.1$21

How this compares

$2,090,339 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$319,411
Medicare patients
901
Services billed
7,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Port Charlotte

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →